| 前列地尔脂微球注射液对慢性阻塞性肺疾病肺动脉高压患者的临床疗效 |
| |
| 引用本文： | 郭韶梅,喻杰.前列地尔脂微球注射液对慢性阻塞性肺疾病肺动脉高压患者的临床疗效[J].矿产勘查,2014,0(7):34-36. |
| |
| 作者姓名： | 郭韶梅 喻杰 |
| |
| 作者单位： | 郭韶梅 (江西省人民医院干部呼吸科,南昌,330006)； 喻杰 (江西省人民医院干部呼吸科,南昌,330006)； |
| |
| 基金项目： | 江西省卫生厅科技支撑计划(项目编号：20113018) |
| |
| 摘 要： | 目的研究前列地尔脂微球注射液（Lipo-PGE1）对慢性阻塞性肺疾病（COPD）肺动脉高压患者的降压效果及其作用机制。方法将190例COPD并肺动脉高压患者按随机数字表法分为Lipo-PGE1加常规治疗组（A组）和常规治疗组（B组）各95例。A组在常规治疗的基础上加用Lipo-PGE1 10μg加生理盐水10mL静脉注射,2次·d^-1;B组给予常规治疗及生理盐水10mL静脉注射,2次·d^-1,疗程均为2周。检测治疗前后2组肺动脉收缩压（SPAP）、肺动脉舒张压（DPAP）、肺动脉平均压（MAP）,测定外周血中循环内皮细胞（CEC）数量以及血浆内皮素-1（ET-1）和一氧化氮（NO）水平。结果与B组比较,A组治疗2周后SPAP、MAP、DPAP、CEC、ET-1明显降低,NO含量明显升高（P〈0.05或P〈0.01）。结论 Lipo-PGE1能够降低COPD并肺动脉高压患者的肺动脉压力,其机制可能与保护血管内皮细胞受损及恢复其内皮源性因子产生及释放功能有关。
|
| 关 键 词： | 前列地尔脂微球注射液 慢性阻塞性肺疾病 肺动脉高压 |
Effect of Lipo Prostaglandin E1 Injection on Pulmonary Arterial Hypertension in Patients with Chronic Obstructive Pulmonary Disease |
| |
| GUO Shao-mei,YU Jie.Effect of Lipo Prostaglandin E1 Injection on Pulmonary Arterial Hypertension in Patients with Chronic Obstructive Pulmonary Disease[J].Mineral Exploration,2014,0(7):34-36. |
| |
| Authors: | GUO Shao-mei YU Jie |
| |
| Affiliation: | (Cadre Respiratory Ward ,J iangxi Provincial People＇s Hospital, Nanchang 330006 ,China) |
| |
| Abstract: | Objective To evaluate the antihypertensive effect of Lipo prostaglandin E1injection（Lipo-PGE1）on pulmonary arterial hypertension（PAH）and its mechanism of action in patients with chronic obstructive pulmonary disease（COPD）.Methods A total of 190COPD patients with PAH were randomly divided into two groups,with 95patients in each group.On the basis of conventional therapy,group A and group B were intravenously injected 10μg Lipo-PGE1dissolved in10mL normal saline and 10mL normal saline twice daily for 2weeks,respectively.Systolic pulmonary artery pressure（SPAP）,diastolic pulmonary artery pressure（DPAP）,mean pulmonary arterial pressure（MAP）,circulating endothelial cells（CEC）in peripheral blood and plasma endothelin-1（ET-1）and nitric oxide（NO）levels were measured before and after treatment.Results Lipo-PGE1treatment for 2weeks decreased SPAP,MAP,DPAP,number of CEC and levels of ET-1and increased levels of NO,compared with group B（P〈0.05or P〈0.01）.Conclusion LipoPGE1can decrease pulmonary artery pressure in patients with COPD through protecting against vascular endothelial cell damage and restoring the production and release of endothelium-derived vasoactive substances. |
| |
| Keywords: | Lipo prostaglandin E1injection chronic obstructive pulmonary disease pulmonary arterial hypertension |
| 本文献已被 维普 等数据库收录！ |
|
